Impact of the canine double-deletion β1 adrenoreceptor polymorphisms on protein structure and heart rate response to atenolol, a β1-selective β-blocker

Kathryn M. Meurs, Joshua A Stern, Yamir Reina-Doreste, Brian A. Maran, Lhoucine Chdid, Sunshine Lahmers, Bruce W. Keene, Katrina L. Mealey

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective β-Adrenergic receptor antagonists are widely utilized for the management of cardiac diseases in dogs. We have recently identified two deletion polymorphisms in the canine adrenoreceptor 1 (ADRB1) gene. We hypothesized that canine ADRB1 deletions would alter the structure of the protein, as well as the heart rate response to the β-adrenergic receptor antagonist, atenolol. The objectives of this study were to predict the impact of these deletions on the predicted structure of the protein and on the heart rate response to atenolol in a population of healthy adult dogs. Methods Eighteen apparently healthy, mature dogs with (11) and without (seven) ADRB1 deletions were evaluated. The heart rate of the dogs was evaluated with a baseline ambulatory ECG before and 14-21 days after atenolol therapy (1 mg/kg orally q12 h). Minimum, average, and maximum heart rates were compared between groups of dogs (deletions, controls) using an unpaired t-test and within each group of dogs using a paired t-test. The protein structure of ADRB1 was predicted by computer modeling. Results Deletions were predicted to alter the structure of the ADRB1 protein. The heart rates of the dogs with deletions were lower than those of the control dogs (the average heart rates were significantly lower). Conclusion ADRB1 deletions appear to have structural and functional consequences. Individual genome-based treatment recommendations could impact the management of dogs with heart disease.

Original languageEnglish (US)
Pages (from-to)427-431
Number of pages5
JournalPharmacogenetics and Genomics
Volume25
Issue number9
DOIs
StatePublished - Aug 19 2015

Fingerprint

Atenolol
Canidae
Heart Rate
Dogs
Proteins
Adrenergic Antagonists
Heart Diseases
Electrocardiography
Genome

Keywords

  • atenolol
  • canine
  • polymorphism
  • β-adrenergic receptor
  • β-blocker

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Genetics(clinical)

Cite this

Impact of the canine double-deletion β1 adrenoreceptor polymorphisms on protein structure and heart rate response to atenolol, a β1-selective β-blocker. / Meurs, Kathryn M.; Stern, Joshua A; Reina-Doreste, Yamir; Maran, Brian A.; Chdid, Lhoucine; Lahmers, Sunshine; Keene, Bruce W.; Mealey, Katrina L.

In: Pharmacogenetics and Genomics, Vol. 25, No. 9, 19.08.2015, p. 427-431.

Research output: Contribution to journalArticle

Meurs, Kathryn M. ; Stern, Joshua A ; Reina-Doreste, Yamir ; Maran, Brian A. ; Chdid, Lhoucine ; Lahmers, Sunshine ; Keene, Bruce W. ; Mealey, Katrina L. / Impact of the canine double-deletion β1 adrenoreceptor polymorphisms on protein structure and heart rate response to atenolol, a β1-selective β-blocker. In: Pharmacogenetics and Genomics. 2015 ; Vol. 25, No. 9. pp. 427-431.
@article{c60b862e6e9d44098ee65de7106f2432,
title = "Impact of the canine double-deletion β1 adrenoreceptor polymorphisms on protein structure and heart rate response to atenolol, a β1-selective β-blocker",
abstract = "Objective β-Adrenergic receptor antagonists are widely utilized for the management of cardiac diseases in dogs. We have recently identified two deletion polymorphisms in the canine adrenoreceptor 1 (ADRB1) gene. We hypothesized that canine ADRB1 deletions would alter the structure of the protein, as well as the heart rate response to the β-adrenergic receptor antagonist, atenolol. The objectives of this study were to predict the impact of these deletions on the predicted structure of the protein and on the heart rate response to atenolol in a population of healthy adult dogs. Methods Eighteen apparently healthy, mature dogs with (11) and without (seven) ADRB1 deletions were evaluated. The heart rate of the dogs was evaluated with a baseline ambulatory ECG before and 14-21 days after atenolol therapy (1 mg/kg orally q12 h). Minimum, average, and maximum heart rates were compared between groups of dogs (deletions, controls) using an unpaired t-test and within each group of dogs using a paired t-test. The protein structure of ADRB1 was predicted by computer modeling. Results Deletions were predicted to alter the structure of the ADRB1 protein. The heart rates of the dogs with deletions were lower than those of the control dogs (the average heart rates were significantly lower). Conclusion ADRB1 deletions appear to have structural and functional consequences. Individual genome-based treatment recommendations could impact the management of dogs with heart disease.",
keywords = "atenolol, canine, polymorphism, β-adrenergic receptor, β-blocker",
author = "Meurs, {Kathryn M.} and Stern, {Joshua A} and Yamir Reina-Doreste and Maran, {Brian A.} and Lhoucine Chdid and Sunshine Lahmers and Keene, {Bruce W.} and Mealey, {Katrina L.}",
year = "2015",
month = "8",
day = "19",
doi = "10.1097/FPC.0000000000000152",
language = "English (US)",
volume = "25",
pages = "427--431",
journal = "Pharmacogenetics and Genomics",
issn = "1744-6872",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Impact of the canine double-deletion β1 adrenoreceptor polymorphisms on protein structure and heart rate response to atenolol, a β1-selective β-blocker

AU - Meurs, Kathryn M.

AU - Stern, Joshua A

AU - Reina-Doreste, Yamir

AU - Maran, Brian A.

AU - Chdid, Lhoucine

AU - Lahmers, Sunshine

AU - Keene, Bruce W.

AU - Mealey, Katrina L.

PY - 2015/8/19

Y1 - 2015/8/19

N2 - Objective β-Adrenergic receptor antagonists are widely utilized for the management of cardiac diseases in dogs. We have recently identified two deletion polymorphisms in the canine adrenoreceptor 1 (ADRB1) gene. We hypothesized that canine ADRB1 deletions would alter the structure of the protein, as well as the heart rate response to the β-adrenergic receptor antagonist, atenolol. The objectives of this study were to predict the impact of these deletions on the predicted structure of the protein and on the heart rate response to atenolol in a population of healthy adult dogs. Methods Eighteen apparently healthy, mature dogs with (11) and without (seven) ADRB1 deletions were evaluated. The heart rate of the dogs was evaluated with a baseline ambulatory ECG before and 14-21 days after atenolol therapy (1 mg/kg orally q12 h). Minimum, average, and maximum heart rates were compared between groups of dogs (deletions, controls) using an unpaired t-test and within each group of dogs using a paired t-test. The protein structure of ADRB1 was predicted by computer modeling. Results Deletions were predicted to alter the structure of the ADRB1 protein. The heart rates of the dogs with deletions were lower than those of the control dogs (the average heart rates were significantly lower). Conclusion ADRB1 deletions appear to have structural and functional consequences. Individual genome-based treatment recommendations could impact the management of dogs with heart disease.

AB - Objective β-Adrenergic receptor antagonists are widely utilized for the management of cardiac diseases in dogs. We have recently identified two deletion polymorphisms in the canine adrenoreceptor 1 (ADRB1) gene. We hypothesized that canine ADRB1 deletions would alter the structure of the protein, as well as the heart rate response to the β-adrenergic receptor antagonist, atenolol. The objectives of this study were to predict the impact of these deletions on the predicted structure of the protein and on the heart rate response to atenolol in a population of healthy adult dogs. Methods Eighteen apparently healthy, mature dogs with (11) and without (seven) ADRB1 deletions were evaluated. The heart rate of the dogs was evaluated with a baseline ambulatory ECG before and 14-21 days after atenolol therapy (1 mg/kg orally q12 h). Minimum, average, and maximum heart rates were compared between groups of dogs (deletions, controls) using an unpaired t-test and within each group of dogs using a paired t-test. The protein structure of ADRB1 was predicted by computer modeling. Results Deletions were predicted to alter the structure of the ADRB1 protein. The heart rates of the dogs with deletions were lower than those of the control dogs (the average heart rates were significantly lower). Conclusion ADRB1 deletions appear to have structural and functional consequences. Individual genome-based treatment recommendations could impact the management of dogs with heart disease.

KW - atenolol

KW - canine

KW - polymorphism

KW - β-adrenergic receptor

KW - β-blocker

UR - http://www.scopus.com/inward/record.url?scp=84939481627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939481627&partnerID=8YFLogxK

U2 - 10.1097/FPC.0000000000000152

DO - 10.1097/FPC.0000000000000152

M3 - Article

VL - 25

SP - 427

EP - 431

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

SN - 1744-6872

IS - 9

ER -